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Abstract
Dystroglycan, an extracellular matrix receptor, has essential functions
in various tissues. Loss of a-dystroglycan-laminin interaction due to
defective glycosylation of a-dystroglycan underlies a group of
congenital muscular dystrophies often associated with brain malfor-
mations, referred to as dystroglycanopathies. The lack of isogenic
human dystroglycanopathy cell models has limited our ability to test
potential drugs in a human- and neural-specific context. Here, we
generated induced pluripotent stem cells (iPSCs) from a severe
dystroglycanopathy patient with homozygous FKRP (fukutin-related
protein gene) mutation. We showed that CRISPR/Cas9-mediated gene
correction of FKRP restored glycosylation of a-dystroglycan in iPSC-
derived cortical neurons, whereas targeted gene mutation of FKRP in
wild-type cells disrupted this glycosylation. In parallel, we screened
31,954 small molecule compounds using a mouse myoblast line for
increased glycosylation of a-dystroglycan. Using human FKRP-iPSC-
derived neural cells for hit validation, we demonstrated that
compound 4-(4-bromophenyl)-6-ethylsulfanyl-2-oxo-3,4-dihydro-1
H-pyridine-5-carbonitrile (4BPPNit) significantly augmented glycosy-
lation of a-dystroglycan, in part through upregulation of LARGE1
glycosyltransferase gene expression. Together, isogenic human
iPSC-derived cells represent a valuable platform for facilitating
dystroglycanopathy drug discovery and therapeutic development.
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Introduction
Post-translational processing of dystroglycan is crucial for its func-
tion as an extracellular matrix (ECM) receptor in a variety of fetal
and adult tissues. The dystroglycan precursor is cleaved into non-
covalently associated a- and b-subunits, forming an integral compo-
nent of a multiprotein complex. The mature a-dystroglycan is a
heavily glycosylated peripheral membrane protein with molecular
weight range from 100 to 156 kDa, dependent on tissue-specific
glycosylation. The b-dystroglycan is a 43-kDa transmembrane
protein that links to the actin cytoskeleton via interaction with
dystrophin [1]. Defective O-linked glycosylation of a-dystroglycan is
a common pathological hallmark associated with number of genetic
syndromes, encompassing symptoms from muscular dystrophies to
ocular defects, cognitive deficits, and structural cortical malforma-
tions (cobblestone lissencephaly) in the central nervous system
(CNS). This group of autosomal recessive disorders are commonly
referred to as secondary dystroglycanopathies [2,3]. Currently, there
is no cure for dystroglycanopathies. The effort of identifying causa-
tive gene mutations in dystroglycanopathies has shed light on a
novel mammalian glycosylation pathway [4,5].
To date, at least 18 genes have been implicated in dystrogly-
canopathies and their products elaborate sequentially the func-
tional glycosylation of a-dystroglycan (core M3 glycan) required
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for binding with (ECM) ligands, e.g., laminins, perlecan, and neur-
exin (Fig 1A) [4,5]. The genes involved include those for dolichol-
phosphate-mannose synthesis: GMPPB, DPM1, DPM2, DPM3 and
DOLK [6–13]; genes required for O-mannosylation and subsequent
sugar addition: POMT1, POMT2, POMGNT1, POMGNT2/GTDC2,
and B3GALNT2 [14–21] and an O-mannose-specific kinase gene:
POMK/SGK196 [21,22]. Recent studies have demonstrated that the
ISPD gene encodes a CDP-ribitol pyrophosphorylase that generates
the reduced nucleotide sugar for the addition of tandem ribitol-5-
phosphate to a-dystroglycan by ribitol-5-phosphate transferases,
encoded by the FKTN and FKRP genes (Fig 1A) [23–30]. Further-
more, TMEM5 and B4GAT1/B3GNT1 genes encode enzymes to
prime the phospho-ribitol with xylose and then glucuronic acid
[27,31–34]. LARGE1 encodes a bifunctional enzyme to synthesize
the subsequent extension of xylose-glucuronic acid disaccharide
repeats that function as the binding sites for laminins (IIH6
epitope) (Fig 1A) [35,36]. Overexpression of LARGE1 in human
cell lines and transgenic mice results in enhanced functional glyco-
sylation of a-dystroglycan and similar genetic strategies have been
proposed as a potential therapeutic approach in dystrogly-
canopathies [37,38].
Among dystroglycanopathies, allelic FKRP mutations are the
more prevalent and cause a wide spectrum of clinical severities
that range from the mild late-onset limb-girdle muscular dystrophy
without neurological deficits (e.g. LGMD2I) to congenital muscular
dystrophy with severe CNS abnormalities (e.g. Walker–Warburg
syndrome) [39]. Malformations of cortical development are
pathological features commonly encountered in patients at the
severe end of the dystroglycanopathy spectrum [40,41]. Although
murine models have been widely used to study mammalian corti-
cal malformations, successful translation from animal models to
patients has been limited. To facilitate drug discovery and develop-
ment for dystroglycanopathy, there is an unmet need for isogenic,
physiology-relevant human cell models to test potential drug candi-
dates in a human- and neural-specific context. Recent studies have
demonstrated success in using patient-specific induced pluripotent
stem cells (iPSCs) to model a variety of neurodevelopment and
neurodegenerative disease and their use in high-throughput screen-
ing [42,43]. We hypothesized that patient-specific iPSC-derived
neural cells can recapitulate pathological hallmarks in dystrogly-
canopathies and can be used for testing potential drug candidates.
Here, we generated the first human FKRP-iPSCs from a dystro-
glycanopathy patient with severe CNS abnormalities. We carried
out CRISPR/Cas9-mediated genome editing [44,45] to correct the
FKRP mutation in FKRP-iPSCs or knock-in the FKRP mutation in
unrelated wild-type iPSCs. We showed that, for the first time,
targeted gene correction of FKRP restores tissue-specific a-dystro-
glycan functional glycosylation in iPSC-derived neural cells,
whereas targeted gene mutation of FKRP in wild-type cells leads to
the expected disruption of functional glycosylation of a-dystro-
glycan. In parallel, we screened 31,954 compounds for increased
glycosylation of a-dystroglycan in the H2K 2B4 mouse myoblast cell
line [46]. We identified and validated a compound, 4-(4-bromo-
phenyl)-6-ethylsulfanyl-2-oxo-3,4-dihydro-1H-pyridine-5-carbonitrile
(4BPPNit; PubChem CID 2837349), that significantly augmented
tissue-specific functional glycosylation of a-dystroglycan in human
FKRP-iPSC-derived neural cells. This effect appears to be secondary
to the upregulated LARGE1 gene expression, suggesting a
mechanism by which 4BPPNit leads to increased functional glycosy-
lation of a-dystroglycan. This proof-of-concept study demonstrates
that isogenic, physiology-relevant human iPSC-based platform can
contribute to facilitating drug development for dystrogly-
canopathies.
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Figure 1. Functional glycosylation of a-dystroglycan
and characterization of dystroglycanopathy patient-specific iPSCs.
A Current model of the core M3 functional glycan structure on a-
dystroglycan and enzymes involved in its synthesis. ECM ligands, such as
laminins, bind to the Xyl-GlucA disaccharide repeats (IIH6 epitope). Man,
mannose; GlcNAc, N-acetylglucosamine; GalNAc, N-acetylgalactosamine;
Rbo5P, ribitol-5-phosphate; Xyl, xylose; GlcA, glucuronic acid.
B Representative images of immunostaining demonstrate that FKRP-iPSCs
express specific pluripotency-associated markers, including NANOG, OCT4,
Tra-1-60, and SSEA4.
C FKRP-iPSCs have a normal karyotype.
D In vitro differentiation of FKRP-iPSCs to cells representing ectoderm (b-III
Tubulin, Tuj1), mesoderm (SMA, smooth muscle actin), and endoderm (AFP,
a-fetoprotein).
Data information: Scale bars, 50 lm.
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Results
Generation and characterization of FKRP-iPSCs derived from a
dystroglycanopathy patient with CNS abnormalities
We obtained dermal fibroblasts from a female individual, previously
diagnosed with congenital muscular dystrophy with CNS abnormali-
ties, including marked cognitive delay, microcephaly, cerebellar
cysts, and cerebellar dysplasia. Clinical features summarized in
Table 1 are consistent with previously reported descriptions
[40,47,48]. Genetic analysis revealed homozygous FKRP c.1364C>A
(p.A455D) mutations in this affected individual; both parents are
heterozygous carriers of this mutation. To generate dystroglycanopa-
thy iPSCs, we reprogrammed the patient’s fibroblasts carrying the
FKRP c.1364C>A mutations using a six-factor reprogramming tech-
nology based on a doxycycline-inducible system [49]. The initial
characterization of five independent FKRP-iPSC clonal lines by qPCR
revealed the gene expression of pluripotency markers, such as
NANOG, OCT4 and REX1 (Appendix Fig S1). Among these clonal
iPSC lines, we focused on the FKRP-iPSC line (clone 1-6). Immunocy-
tochemistry confirmed the expression of pluripotency markers, such
as NANOG, OCT4, Tra-1-60 and SSEA4 in this FKRP-iPSC line
(Fig 1B), which exhibited the normal karyotype (Fig 1C). In addition,
in vitro differentiation of the FKRP-iPSCs formed embryoid bodies
with cell types representing all three embryonic germ layers, con-
firmed by immunocytochemistry in specific cell lineage markers,
such as b-III tubulin (Tuj1) for ectoderm, smooth muscle actin (SMA)
for mesoderm, and a-fetoprotein (AFP) for endoderm (Fig 1D).
Targeted gene correction of FKRP-iPSCs using CRISPR/Cas9-
mediated genome editing
A common issue of patient-specific iPSCs in disease modeling is the
lack of appropriate isogenic control cells, causing concerns about
the effect of genetic backgrounds on phenotypic variability [50]. To
overcome this issue, we applied a precise genome-editing strategy to
correct the FKRP c.1364C>A (p.A455D) mutation using site-specific
endonuclease CRISPR/Cas9 stimulated homologous recombination
[44,45], which consists of a single-guide RNA (sgRNA), the Cas9
nuclease, and a donor-targeting vector. To minimize potential off-
target effects, we used an optimized computational algorithm
(http://crispr.mit.edu) to identify appropriate sgRNAs for utilizing
the CRISPR/Cas9 to generate DNA double-strand breaks (DSB) near
the FKRP mutation (Fig 2A). The sgRNA used in this study has high
on-target and low off-target scores (Appendix Table S1). A trans-
poson-based selection cassette piggyBac (PGK-puroΔtk) was used in
the targeting donor vector to enable both positive and
negative selections to facilitate the screening process for edited
events [51].
We PCR-amplified two 1-kb fragments flanking the CRISPR/Cas9
target site close to the FKRP c.1364C>A allele, which was simultane-
ously corrected (FKRP c.1364C). The two fragments (homology left
and right arms) flanking a piggyBac (PGK-puroΔtk) selection cassette
were assembled together into a targeting donor vector (Fig 2B).
DNA sequences at the junctions between piggyBac (PGK-puroΔtk)
selection cassette and homology arms were modified to accommo-
date TTAA sequences, yet coding the same amino acids after
excision of the selection cassette (Fig 2B). We electroporated the
site-specific CRISPR/Cas9 plasmids with the targeting donor vector
(FKRP c.1364C) into the iPSCs. By positive selection with puro-
mycin, iPSCs with an integrated donor vector formed puromycin-
resistant clones, which were picked for rapid PCR genotyping
(Appendix Fig S2A and B). We identified 3 homozygously and 27
heterozygously targeted independent clones (Appendix Table S2),
which were confirmed by sequencing (data not shown). To excise
the piggyBac (PGK-puroΔtk) selection cassette, 2 homozygously
targeted FKRP (c.1364C)-iPSC clones (5.19 and 3.16) were electropo-
rated with piggyBac transposase expression plasmid, followed by
negative selection in culture media containing 1-(2-Deoxy-2-fluoro-
b-D-arabinofuranosyl)-5-iodo-2,4(1H,3H)-pyrimidinedione (FIAU), a
thymidine analogue that is processed to toxic metabolites in the
presence of piggyBac (PGK-puroΔtk). PCR genotyping identified 11
biallelicly corrected-iPSC clones that had the selection cassette
completely excised without re-integration (Appendix Fig S2C and
Table S2). The biallelicly corrected-iPSC clones (5D17, 5D23, and
3B17) were sequenced to confirm a precise correction of the FKRP
mutation and the engineered selection cassette excision site
(Fig 2C). The biallelicly corrected-iPSC lines retained normal
karyotypes (Fig 2D). In addition, sequencing of the top 5 potential
off-target sites (Appendix Table S1) confirmed that no mutations
were introduced during genome editing (data not shown).
Generation of neural stem cells and cortical neurons from FKRP-
and CRISPR/Cas9 corrected-iPSCs
To investigate the potential of iPSCs for modeling neural pathogene-
sis in dystroglycanopathies, we used a serum-free neural induction
medium to derive primitive neural stem cells (NSCs) from iPSCs
[52]. Immunocytochemistry confirmed that NSCs derived from
FKRP- and CRISPR/Cas9 corrected-iPSC lines expressed the classic
NSC markers, including SOX1, SOX2, and nestin (Fig 3A and B). In
terms of the efficiency of neural induction, no discernible difference
Table 1. Clinical features of the affected individual with FKRP
mutations.
Subject
FKRP variants c.1364C>A (p.A455D)
Zygosity Homozygous
Sex Female
Age at assessment 11 months
Symptoms at presentation Hypotonia; floppiness; paucity of
spontaneous movements
Feeding difficulties From first few months of life
Respiratory difficulties Frequent chest infection from 6 months
Orthopedic complications Hip subluxation
Max functional achievement Partial antigravity in arms and legs;
unable to sit
Serum CK (NR < 200 U/l) 5000-7090
CNS function Partially alert
Head circumference Microcephaly
MRI Cerebellar cysts and cerebellar dysplasia
Muscle biopsy Dystrophic; severely reduced IIH6 staining
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was observed between NSCs derived from FKRP- and the three
corrected-iPSC lines, 5D17, 5D23, and 3B17 (Fig 3C and D). Quan-
tification of SOX1- and SOX2-positive NSCs showed >99% efficiency
from both FKRP- and three corrected-iPSC lines (Fig 3C and D).
Subsequently, we directed the differentiation of FKRP- and
corrected-NSC lines toward cortical projection neurons using a
well-established protocol, which recapitulates important stages in
human cortical development [53]. After switching to the Neural
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Figure 2. Targeted gene correction of FKRPA455D-iPSCs by CRISPR/Cas9-mediated genome editing.
A Cas9 protein and the specific sgRNA targeting the human FKRP locus. The FKRP c.1364C>A (p.A455D) mutation is 43 bases upstream of the sgRNA target sequences.
Red arrowheads indicate putative cleavage site. PAM, protospacer-adjacent motif.
B A schematic diagram shows the genome-editing strategy based on CRISPR/Cas9-stimulated homologous recombination, followed by positive selection with
puromycin and negative selection with FIAU. Homology left and right arms on the targeting donor vector are indicated as black boxes, flanking the piggyBac (PGK-
puroΔtk) selection cassette, which is under the control of PGK promoter. PCR genotyping primers are shown as blue arrows. Note that the TTAA sequences are
designed to accommodate the selection cassette excision sites, yet code the same amino acids.
C Sequence analysis shows precise biallelic correction of the FKRP mutation in three independently corrected-iPSC clones (5D17, 5D23, and 3B17), compared with their
parental FKRPA455D-iPSCs. Selection cassette excision sites are identified in the corrected-iPSC lines.
D CRISPR/Cas9 corrected-iPSC lines show a normal karyotype.
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Figure 3. Characterization of NSCs and cortical neurons derived from FKRP- and CRISPR/Cas9 corrected-iPSCs.
A, B Representative images of NSCs derived from FKRP- and corrected-iPSC lines expressing SOX1, SOX2, and nestin.
C, D Quantification of percentage of SOX1+ (C) and SOX2+ (D) cells in culture. The efficiency of neural induction is more than 99% in FKRP- and corrected-iPSC (5D17,
5D23, and 3B17) lines. Data are mean  s.d. n = 4 technical replicates.
E, F FKRP- and corrected-NSC lines can be further differentiated to cortical neural progenitor cells, expressing PAX6, OTX2, and vimentin.
G–I Quantification of percentage of PAX6+ (G) and OTX2+ (H) cells in culture. About 91-98% of cells derived from FKRP, 5D17, 5D23, and 3B17 NSC lines express PAX6 (G).
About 93-96% of cells derived from FKRP, 5D17, 5D23, and 3B17 NSC lines express OTX2 (H). Of the OTX2+ population, about 60-67% cells are also Ki67+ cycling
progenitors (I). Data are mean  s.d. n = 4 technical replicates.
J, K Glutamatergic projection neurons derived from FKRP and corrected (5D17, 5D23, and 3B17) progenitor cells. The vast majority of neurons contain vGlut1+ punctae
in their neurites (labeled by Tuj1). Right panels are enlarged images from the insets of left panels.
Data information: Scale bars, 50 lm.
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Maintenance Medium for one week, we confirmed the identity of
FKRP- and corrected-iPSC-derived cortical stem and progenitor
cells, which expressed the classic cortical stem cell markers, PAX6,
OTX2, and vimentin (Fig 3E and F); the proliferating cells were
Ki67-positive (Fig 3E and F). The efficiency of cortical induction
between FKRP and three lines of corrected cortical progenitors
were very similar. The PAX6+ cells in culture were about 91-98%,
and OTX2+ cells are about 93-96% (Fig 3G and H); 60-67% of
OTX2+ cells were also Ki67+ cycling progenitors (Fig 3I). After
three weeks in Neural Maintenance Medium, FKRP and corrected
progenitor-derived cells showed punctate staining of vesicular
glutamate transporter 1 (vGlut1) in their neurites labeled by
neuron-specific tubulin, Tuj1 (Fig 3J and K). This confirmed the
generation of glutamatergic projection neurons during cortical
neurogenesis in culture. Although the FKRP(A455D) variant does
not appear to be required during early neurogenesis, we cannot
exclude that this mutation might be responsible for pathological
phenotypes at a later stage.
Tissue-specific functional glycosylation of a-dystroglycan is
restored in cortical neurons derived from CRISPR/Cas9-
corrected-iPSCs
Next, we investigated the presence of functional glycosylation
of a-dystroglycan in cortical neurons derived from our
corrected-iPSC lines using immunoblotting with the IIH6 anti-
body, which recognizes the laminin-binding glyco-epitope on a-
dystroglycan [54]. Wild-type mouse muscle and brain lysates
were used as positive controls to show differential glycosylation
of a-dystroglycan in a tissue-specific manner. In addition, lysate
of cortical neurons derived from a non-isogenic, human wild-
type iPSC line (WT-iPSCs) was included [49]. We showed that
the molecular weight of glycosylated a-dystroglycan in WT-
iPSC-derived cortical neurons is similar to that in mouse brain
lysate (~120 kDa) and less than that in muscle lysate
(~156 kDa) (Fig 4A), consistent with previously reported tissue-
specific glycosylation of a-dystroglycan [1]. Furthermore, IIH6
reactivity on immunoblot was almost not detected in cortical
neurons derived from FKRP-iPSCs (Fig 4A and B). In contrast,
cortical neurons derived from CRISPR/Cas9-corrected-iPSC lines
showed clear IIH6 reactivity of the expected molecular size
(~120 kDa), indicating restored glycosylation of a-dystroglycan
(Fig 4B).
Following the detection of glycosylated a-dystroglycan in
corrected cortical neurons, we then investigated whether the
laminin-binding activity is associated with the IIH6 glyco-epitope on
a-dystroglycan. We confirmed that laminin-binding was disrupted
in cortical neurons derived from FKRP-iPSCs (Fig 4C), whereas
cortical neurons derived from corrected-iPSC lines showed strong
laminin-binding activity at ~120 kDa similar to mouse brain, but
lower than mouse muscle (~156 kDa) (Fig 4C). Together, these
results demonstrated a restoration of tissue-specific functional glyco-
sylation of a-dystroglycan in CRISPR/Cas9-corrected cortical
neurons.
Targeted gene mutation of FKRP disrupts functional
glycosylation of a-dystroglycan in cortical neurons derived
from iPSCs
To independently validate the results from our FKRP- and corrected-
iPSC-derived cortical neurons, the same genome-editing strategy
was used to knock-in the FKRP c.1364C>A (p.A455D) mutation into
the WT-iPSCs [49] (Appendix Fig S3A). A donor-targeting vector
carrying the FKRP mutation for CRISPR/Cas9-mediated homologous
recombination was constructed. We then electroporated the site-
specific CRISPR/Cas9 plasmids with the targeting donor vector
(FKRP c.1364C>A) into the WT-iPSCs (Appendix Fig S3B). Using
puromycin-positive selection and PCR genotyping (Appendix Fig
A B C
Figure 4. Functional glycosylation of a-dystroglycan in cortical neurons derived from CRISPR/Cas9-corrected-iPSCs.
A Molecular weight of glycosylated a-dystroglycan (IIH6 epitope) in WT-iPSC-derived cortical neurons is similar to that in the mouse brain (~120 kDa) and lower than
that in the mouse muscle (~156 kDa). IIH6 reactivity was almost not detected in cortical neurons derived from FKRP-iPSCs. Note that the b-actin antibody does not
cross-react with the muscle sample.
B Representative immunoblots show that targeted gene correction of FKRP restores IIH6 reactivity in iPSC-derived cortical neurons. Intensities of IIH6 reactivity are
normalized to b-actin expression, indicating mean  s.d. (n = 3 biological replicates; t-test; **P < 0.01).
C Representative laminin overlays show that targeted gene correction restores laminin-binding activity in iPSC-derived cortical neurons. Intensities of laminin-binding
activity are normalized to b-dystroglycan, indicating mean  s.d. (n = 3 biological replicates; t-test; *P < 0.05).
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S3C), 2 homozygously targeted clones (a15 and c43) were identified
and expanded for selection cassette excision (Appendix Table S3).
Following FIAU-negative selection and PCR genotyping
(Appendix Fig S3C), we identified 2 biallelicly FKRP mutated-iPSC
clones (C29 and C31) that have the selection cassette completely
excised without re-integration (Appendix Table S3). The FKRP
mutated-iPSC clones (C29 and C31) were sequenced to confirm the
biallelic knock-in of FKRP c.1364C>A (p.A455D) mutations and the
engineered selection cassette excision site (Appendix Fig S3D). The
WT- and FKRP mutated-iPSC lines were differentiated to NSCs
(Appendix Fig S4A and B) and subsequently to cortical neurons for
functional analysis. Compared with cortical neurons derived from
WT-iPSCs, targeted gene mutation of FKRP disrupted the IIH6 reac-
tivity (Appendix Fig S4C) and laminin-binding activity
(Appendix Fig S4D) in cortical neurons derived from FKRP mutated-
iPSC lines. This indicated loss of functional glycosylation of a-
dystroglycan. Together, our results demonstrated that target gene
mutation of FKRP by CRISPR/Cas9-mediated genome editing could
recapitulate pathological hallmarks of dystroglycanopathy in human
iPSC-derived cortical neurons.
High-throughput screening using H2K 2B4 mouse myoblast cell
line for increased glycosylation of a-dystroglycan
In parallel to generation of FKRP dystroglycanopathy human iPSC
models, we sought to perform a high-throughput phenotypic screen-
ing to identify compounds capable of increasing the functional
glycosylation of a-dystroglycan (detected by IIH6 immunostaining).
Using an automated high-content microscopy platform, we screened
a library of 31,954 chemical compounds with the immortalized
mouse H2K 2B4 myoblast cell line in 384-well plates (Fig 5A). The
compounds were screened at 10 lM and incubated with the H2K
2B4 cells for 24 h. Each plate also contained cells treated with 0.2%
dimethyl sulfoxide (DMSO) as negative controls and cells incubated
with 5 lM Trichostatin A [55] as positive controls. Following
immunostaining and image acquisition, an automated image analy-
sis algorithm was used to detect the fluorescent intensity of the IIH6
immunostaining. A total of 683 compounds (2.1%) were selected
for further analysis (Fig 5B). Next, two independent inspectors
performed a series of visual examinations on algorithm-selected
images. We excluded images with non-specific staining or autofluo-
rescence and scored for the localization of IIH6 staining and percent-
age of IIH6-positive cells. From these, IIH6 fluorescent intensity
values of the acquired images were compared to the negative and
positive controls in the same plates and 11 compounds were
assessed in a dose–response assay with seven different concentra-
tion points (Fig 5C). Three hits with highest increase in IIH6
immunostaining were pursued further, i.e., (5Z)-5-[(3-ethoxy-4-
hydroxy-phenyl)methylene]-3-(4-fluorophenyl)-2-thioxo-thiazolidin-
4-one (HPFPTzone) (Fig 5D, Structure 1), 4BPPNit (Fig 5D,
Structure 2), and (5E)-5-[(2,5-dimethyl-1-phenyl-pyrrol-3-yl)
methylene]-3-phenyl-2-thioxo-thiazolidin-4-one (DPPTzone) (Fig 5D,
Structure 3). Next, flow cytometry analysis was used as the
secondary assay to detect the IIH6-reactive glycans on H2K 2B4 cells
treated with these three compounds, compared with untreated cells.
4BPPNit confirmed as hit by showing significantly increased mean
fluorescence intensity of IIH6-reactive glycans, while there was no
difference in the percentage of IIH6-positive cells (Fig 5E).
HPFPTzone and DPPTzone were discarded for inconsistent results
(data not shown). Therefore, 4BPPNit was the most promising hit
compound.
4BPPNit augments functional glycosylation of a-dystroglycan in
human FKRP-iPSC-derived neural stem cells
Next, we explored whether the FKRP dystroglycanopathy human
iPSC models could be used to demonstrate restoration of functional
glycosylation of a-dystroglycan by small molecule compounds.
FKRP- and corrected-NSC lines were treated with the hit compound
4BPPNit (20 lM, based on the dose–response and flow cytometry
analysis) for 24, 48, and 72 h and compared with DMSO only
controls. There was no discernible cell toxicity between compound-
treated and non-treated control cells. Immunoblotting with the IIH6
antibody detected glycosylated a-dystroglycan (~120 kDa) in
corrected-NSCs (3B17), whereas the IIH6 reactivity was strongly
reduced in FKRP-NSCs (Fig 6A). Compared with untreated control,
increased IIH6 reactivity was detected in the 4BPPNit-treated FKRP-
NSCs, but much weaker than that in CRISPR-corrected-NSCs
▸Figure 5. High-throughput screen identifies compounds increasing glycosylation of a-dystroglycan.A Schematic of the screening procedure. Compounds were dispensed in Matrigel-coated 384-well plates prior to seeding of murine myoblasts. Myoblasts were
incubated for 24 h with 10 lM of the individual compounds, 5 lM of the positive control Trichostatin A or with the negative control DMSO. After fixation and
staining with the IIH6 antibody, detecting glycosylated a-dystroglycan, the cells were imaged using the confocal PE Opera LX high-throughput microscope. The
intensity of the a-dystroglycan glycosylation staining was determined, values normalized, and a hit list generated. Scale bar, 20 lm.
B Compound validation strategy. After the primary screen, the a-dystroglycan glycosylation staining pattern of initially identified compounds was examined to exclude
autofluorescent as well as toxic compounds. From the remaining compounds, 11 hit compounds were nominated after acquired images were compared to controls in
the respective screening plate. A dose–response assay followed by flow cytometry assays further narrowed down hits to 1 compound.
C Dose–response curve. H2K 2B4 cells were treated with serial dilutions of 11 hit compounds for 24 h and fixed, stained, and imaged as described above. The average
values and standard deviations of the mean fluorescent intensities of technical triplicates were calculated and a non-linear regression curve was fitted for the three
compounds showing the highest increase in a-dystroglycan glycosylation (IIH6 immunostaining). Representative images of cells treated with 5 lM of the respective
compounds as well as EC50 values are shown. HPFPTzone: (5Z)-5-[(3-ethoxy-4-hydroxy-phenyl)methylene]-3-(4-fluorophenyl)-2-thioxo-thiazolidin-4-one. 4BPPNit:
4-(4-bromophenyl)-6-ethylsulfanyl-2-oxo-3,4-dihydro-1H-pyridine-5-carbonitrile. DPPTzone: (5E)-5-[(2,5-dimethyl-1-phenyl-pyrrol-3-yl)methylene]-3-phenyl-2-thioxo-
thiazolidin-4-one. Regression curve and EC50 values were calculated using GraphPad Prism 7 software. In images shown, green represents glycosylated a-
dystroglycan and blue Hoechst staining. Scale bar, 50 lm.
D Structures of the 3 compounds showing the highest increase in a-dystroglycan glycosylation. Structure 1: HPFPTzone. Structure 2: 4BPPNit. Structure 3: DPPTzone.
E Flow cytometry analysis confirmed that 4BPPNit treatment (20 lM) significantly increased IIH6-reactive glycan in mouse H2K 2B4 cells, compared with untreated
cells. There was no significant difference in the percentage of IIH6-positive cells. Values indicate mean  s.e.m. (n = 6, triplicates of 2 independent experiments;
t-test; NS, not significant; **P < 0.01).
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(Fig 6A; Appendix Fig S5A). Under the same exposure time, the
signal intensity of IIH6 reactivity is saturated in corrected-NSCs and
its relative level is underestimated (Fig 6A). Thus, we decided to
quantify the effects of 4BPPNit treatment in FKRP-NSCs and
CRISPR-corrected-NSCs separately (Fig 6B–G). FKRP-NSCs treated
with 4BPPNit showed a significantly increased IIH6 reactivity
A
B
D E
C
Figure 5.
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Figure 6. Hit compound 4BPPNit validation in the FKRP dystroglycanopathy human iPSC models.
A FKRP-NSCs treated with 4BPPNit showed increased IIH6 reactivity, compared with untreated control cells. Note that the augmented IIH6 reactivity by 4BPPNit is
much weaker than that in CRISPR-corrected-NSCs. Under the same exposure time, the signal intensity of IIH6 reactivity is saturated in corrected-NSCs.
B Representative immunoblots with the IIH6 antibody using FKRP- and corrected-NSCs treated with 4BPPNit for 24, 48, and 72 h, and DMSO only controls.
C Quantification of a-dystroglycan glycosylation (IIH6), compared with DMSO only controls.
D Representative immunoblots of laminin-binding analysis using FKRP- and corrected-NSCs treated with 4BPPNit and DMSO only controls.
E Quantification of laminin-binding activities, compared with DMSO only controls.
F Representative immunoblots with the AF6868 antibody detecting both a-dystroglycan core protein and b-dystroglycan in FKRP- and corrected-NSCs treated with
4BPPNit and DMSO only controls.
G Quantification of a-dystroglycan core protein and b-dystroglycan expression, compared with DMSO only controls.
Data information: Intensities of glycosylation, laminin-binding activity, or protein expression are normalized to GAPDH protein expression. Note that the left and right
panels of the immunoblots in (B) and (D) are not equivalent exposure time. See also Appendix Fig S5. Values indicate mean  s.d. (n = 3 or 4 biological replicates; one-
way ANOVA; NS, not significant; *P < 0.05; **P < 0.01).
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(~2-fold) at 48 and 72 h, compared with the untreated control (Fig 6B
and C). A trend of slightly increased IIH6 reactivity in corrected-NSCs
was observed, but this was not statistically significant (Fig 6B and C).
Next, we confirmed significantly enhanced laminin-binding activity in
FKRP-NSCs treated with 4BPPNit for 72 h, consistent with the
increased IIH6 reactivity (Fig 6D and E). Treatment of 4BPPNit in
corrected-NSCs increased the laminin-binding activity slightly, but this
was not statistically significant (Fig 6D and E). Taken together, the
increased IIH6 reactivity is correlated with enhanced laminin-binding
activity in compound-treated FKRP-NSCs.
Next, we sought to distinguish whether the increased IIH6 reac-
tivity and laminin-binding were due to increased glycosylation of a-
dystroglycan or elevated dystroglycan core protein expression. To
do this, we used a polyclonal antibody (AF6868) that recognizes
both a-dystroglycan core protein and b-dystroglycan. Treatment of
4BPPNit at three time points did not significantly increase a-dystro-
glycan core protein or b-dystroglycan expression levels in FKRP-
NSCs (Fig 6F and G). Similar results were observed in corrected-
NSCs treated with 4BPPNit (Fig 6F and G). Note that the weak
increase of IIH6 reactivity induced by 4BPPNit (Fig 6A;
Appendix Fig S5A) was not sufficient to shift the molecular weight
of a-dystroglycan core protein in FKRP-NSCs (Appendix Fig S5B).
Together, these data indicate that 4BPPNit is capable of inducing
tissue-specific functional glycosylation of a-dystroglycan in human
FKRP-iPSC-derived NSCs, although the effect of 4BPPNit is much
weaker than the CRISPR correction of FKRP.
4BPPNit induces upregulation of LARGE1 gene expression
The function of 4BPPNit has not been reported previously. Studies
have shown that overexpression of mutant FKRP can improve func-
tional glycosylation of a-dystroglycan in FKRP mutant mice [56] and
that overexpression of LARGE1 in human cell lines can lead to
enhanced functional glycosylation of a-dystroglycan [37]. In an
attempt to address potential mechanisms by which 4BPPNit can
induce functional glycosylation of a-dystroglycan, we hypothesized
that 4BPPNit treatment may directly or indirectly upregulate gene
expression levels of FKRP and/or LARGE1 both of which are
involved in synthesizing the core M3 glycan on a-dystroglycan.
Consistent with immunoblotting analysis using the AF6868 anti-
body, dystroglycan (DAG1) gene expression was not significantly
changed in either FKRP- or corrected-NSCs treated with 4BPPNit at
three time points using quantitative real-time PCR (Fig 7A). Next,
FKRP gene expression levels were measured in compound-treated
FKRP- or corrected-NSCs. When compared with untreated cells, no
significant differences were detected (Fig 7B). Interestingly, we
found that 4BPPNit treatment significantly upregulated LARGE1 gene
expression levels in FKRP-NSCs treated for 48 h (~1.5-fold) and 72 h
(~1.7-fold) and in corrected-NSCs treated for 72 h (~1.8-fold), when
compared with untreated controls (Fig 7C; Appendix Fig S6). Analy-
sis of other genes involved in the synthesis of core M3 glycan on a-
dystroglycan showed a mild but significant increase of B4GAT1,
TMEM5, FKTN, and POMGNT2 expression in CRISPR-corrected-NSCs
treated with 4BPPNit, but no significant difference was detected in
FKRP-NSCs treated with 4BPPNit (Appendix Fig S6). Together, these
results suggest that 4BPPNit treatment may increase functional
glycosylation of a-dystroglycan in FKRP-NSCs through upregulation
of LARGE1 gene expression (see Discussion).
Discussion
In this study, we have developed a novel isogenic, human FKRP-
iPSC-based platform for modeling dystroglycanopathy and testing
potential drug candidates. We report here that CRISPR/Cas9-
induced homologous recombination together with the piggyBac posi-
tive/negative selection cassette is a powerful and versatile strategy,
which allows precise modification of the mammalian genome at a
single base pair level without leaving footprints. For the first time,
we demonstrate a precise genome editing at the FKRP locus in
human iPSCs. Most reported FKRP pathogenic variants are missense
mutations. Among these mutations, the FKRP c.826C>A (L276I)
mutation is the most common variant and causes a mild form of
dystroglycanopathy (LGMD2I), which is among the most common
LGMD forms especially in the Caucasian population. Our genome-
editing strategy can be applied to precisely correct these FKRP
A
B
C
Figure 7. Compound 4BPPNit induces upregulation of LARGE1 gene
expression.
A DAG1 gene expression analysis in FKRP- and corrected-NSCs treated with
4BPPNit, compared with DMSO only controls.
B FKRP gene expression analysis in FKRP- and corrected-NSCs treated with
4BPPNit, compared with DMSO only controls.
C LARGE1 gene expression analysis in FKRP- and corrected-NSCs treated with
4BPPNit, compared with DMSO only controls.
Data information: Gene expression levels are normalized to ACTB gene
expression. Values indicate mean  s.e.m. (n = 6 biological replicates; one-
way ANOVA; NS, not significant; *P < 0.05; **P < 0.01).
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missense mutations and by implication small insertion/deletion
mutations (INDELs), as well as similar type of mutations in other
dystroglycanopathy genes. Recent advances in the delivery of Cas9-
sgRNA ribonucleoproteins (Cas9 RNPs) may further improve the
efficiency of biallelic gene targeting [57].
The process of cellular reprogramming from fibroblasts to
iPSCs followed by directed differentiation from iPSCs to NSCs and
subsequently to cortical neurons involves dramatic changes to the
gene expression profile of a cell. The functional glycosylation of
a-dystroglycan is a consequence of a complex biosynthetic path-
way orchestrated by many enzymes to form the laminin-binding
moiety [5]. Our results indicate that genes involved in functional
glycosylation of a-dystroglycan are expressed during in vitro
corticogenesis. Interestingly, the molecular weight of a-dystro-
glycan varies due to tissue-specific O-glycosylation [1]. Consistent
with previous studies, we have shown that the molecular weight
of glycosylated a-dystroglycan in human iPSC-derived neural cells
is similar to that in the mouse brain. Importantly, targeted gene
correction of FKRP restores tissue-specific functional glycosylation
of a-dystroglycan in iPSC-derived neurons, whereas targeted gene
mutation of FKRP in unrelated wild-type cells disrupts this glyco-
sylation. Our findings have significant implications in using
human iPSCs for modeling dystroglycanopathies because the
in vitro cellular model can recapitulate the in vivo pathological
hallmarks of the target tissues.
Mutations in FKRP and other known causative genes together
account for approximately 50-60% of severe forms of dystrogly-
canopathies [29,33]. Previously, a zebrafish-based study showed
genetic interactions between ISPD, FKTN, and FKRP [29]. Subse-
quent studies demonstrated the enzymatic function of ISPD, FKTN,
and FKRP, which synergistically add tandem ribitol-5-phosphate
onto a-dystroglycan [24,25]. Furthermore, a recent study showed
that excess amount of ribitol treatment in the FKRP(P448L) mutant
mice can increase levels of ribitol-5-phosphate and CDP-ribitol,
leading to enhanced functional glycosylation of a-dystroglycan
associated with improved muscle pathology and function [58]. This
therapeutic strategy is based on the residual enzymatic function of
FKRP mutant proteins. In the present study, we showed that we
have identified a hit compound 4BPPNit by high-throughput small
molecule screening and demonstrated the use of FKRP dystrogly-
canopathy human iPSC-derived neural cells for validating this
compound. Moreover, treatment of 4BPPNit can significantly
induce upregulation of LARGE1 gene expression in FKRP-NSCs,
which is correlated with significantly increased functional glycosy-
lation of a-dystroglycan. A combinatorial approach utilizing ribitol
and 4BPPNit may have synergistic effects for augmenting functional
glycosylation of a-dystroglycan. Interestingly, despite significant
upregulation of LARGE1 transcript in corrected-NSCs treated with
4BPPNit, this does not markedly enhance functional glycosylation
of a-dystroglycan, suggesting a possible feedback mechanism for
regulating the extension of xylose-glucuronic acid disaccharide
repeats transferred by LARGE1 in the healthy condition.
We report here the first FKRP dystroglycanopathy human iPSC
models and its suitability to assess functional glycosylation of a-
dystroglycan using genetic and chemical correction. Although
4BPPNit treatment augmented functional glycosylation of a-dystro-
glycan (chemical correction), the effect is not sufficient to shift the
molecular weight of a-dystroglycan core protein to normal levels as
in CRISPR-corrected cells (genetic correction). Future studies using
our isogenic pairs of human iPSC models hold significant promise in
early-stage drug discovery and for validation of potential small mole-
cule drug candidates. Furthermore, it has been shown that downreg-
ulation of LARGE1 and hypoglycosylation of a-dystroglycan are
involved in cancer progression and metastasis [55,59]. Therefore,
the identification of compounds with a similar mechanism of action
as 4BPPNit may be applicable for developing cancer therapies.
Moreover, the isogenic pairs of human iPSCs generated in this
study have enormous potential in other research avenues. Apart
from degeneration of skeletal muscle, dilated cardiomyopathy is a
frequent associated feature of FKRP-deficient dystroglycanopathy
[60]. To study mechanisms underlying muscle degeneration and
dilated cardiomyopathy, the isogenic pairs of corrected- and FKRP-
iPSCs can be differentiated to myogenic and cardiac cells [61,62].
Importantly, this will facilitate drug discovery and development for
treating a variety of diseases, in which loss of a-dystroglycan-
laminin-binding activity underlies the disease pathogenesis.
Materials and Methods
Generation of human FKRP-iPSC lines
We obtained FKRP patient fibroblast lines from the MRC Centre for
Neuromuscular Diseases Biobank (REC reference 06/Q0406/33) and
ethical approval for the use of these cells (REC reference 13/LO/1826;
IRAS project ID: 141100). All patients or their legal guardians gave
written informed consent. To generate patient-specific induced
pluripotent stem cells (iPSCs), we implemented an efficient repro-
gramming technology based on a doxycycline-inducible system using
six factors, OCT4, SOX2, KLF4, c-MYC, RARG, and LRH1 [49]. In vitro
differentiation and analysis were carried out as described [49].
Vector construction and CRISPR/Cas9-mediated genome editing
For targeted gene correction, we used Gibson Assembly (New England
BioLabs) to construct the targeting donor vector. Briefly, the 1-kb left
and right homology arms (LHA and RHA) were PCR-amplified from
parental FKRP fibroblast. The FKRP c.1364C>A (p.A455D) mutation on
the LHA was simultaneously corrected with a modified primer
(Appendix Table S4). The piggyBac (PGK-puroΔtk) selection cassette
and vector backbone were PCR-amplified from the pMCS-AAT_PB-
PGKpuroTK plasmid [63]. The four PCR fragments have 40-bp overlap-
ping from end to end (primers are listed in Appendix Table S4) and
joined together using Gibson Assembly Master Mix. The hCas9 plasmid
was a gift from George Church (Addgene plasmid # 41815) [45]. Short
DNA fragments containing the FKRP sgRNA target sequence
(Appendix Table S1) were generated by annealing two primers
(Appendix Table S4), which create two overhangs ready for cloning
into BsaI-digested p1261_U6_BsaI_gRNA_plasmid (kind gift from
Sebastian Gerety, Wellcome Trust Sanger Institute). The expression of
sgRNA is under the control of U6 promoter. The cell suspension was
transferred to a cuvette and electroporated using Amaxa Nucleofection
2b device with program B16. For targeted gene mutation, the same
strategy was used to construct the donor-targeting vector carrying the
FKRP c.1364C>A (p.A455D) mutation on LHA using primers in
Appendix Table S4.
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Karyotyping analysis
As previously described [64], multiplex fluorescent in situ hybridiza-
tion (M-FISH) karyotype analysis was performed on iPSC lines with
slight modification. Briefly, prior to metaphase harvesting, iPSCs
were grown in M15 medium (knockout DMEM, 15% fetal bovine
serum, 1X glutamine–penicillin–streptomycin, 1X non-essential
amino acids, and 1 ng/ml human recombinant LIF) for 24 h and
then treated with 10 lM Y-27632 dihydrochloride (Tocris) for 2–3 h.
Neural induction and cortical differentiation from human iPSCs
As described [52], induction of NSCs from human iPSCs was carried
out using Gibco Neural Induction Medium (Neurobasal medium and
2% neural induction supplement) for 7 days, followed by passaging
and expansion in neural expansion medium (49% Neurobasal
medium, 49% Advanced DMDM/F-12 and 2% neural induction
supplement). Expanded NSCs were cryopreserved or differentiated
into cortical neurons following the established protocol [53]. Briefly,
tissue culture plates were pre-coated with 0.01% (w/v) poly-L-
ornithine (Sigma, P4957) for 4 h, followed by 20 lg/ml of laminins
(Sigma, L2020) for 4 h. NSCs were seeded on the pre-coated plates
(50,000/cm2) in neural expansion medium with 5 lM Y-27632 dihy-
drochloride (Tocris) for 24 h. Subsequently, neural expansion
medium was replaced with neural maintenance medium, containing
50% DMEM/F-12 (Gibco), 50% Neurobasal medium (Gibco), 0.5X
N2 supplement (Gibco), 0.5X B27 supplement (Gibco), 1.5 mM
GlutaMAX-I (Gibco), 0.5X penicillin–streptomycin (Gibco), 2.5 lg/
ml insulin (Sigma), 0.05 mM of 2-mecaptoethanol (Gibco), 0.5% v/
v of non-essential amino acid (Gibco), 20 ng/ml BDNF (Peprotech),
and 20 ng/ml GDNF (Peprotech). When reaching 90% confluence
(approximately within 3–4 days), cells were re-seeded (60,000/cm2)
in neural maintenance medium (with 5 lM Y-27632 dihydrochloride
for 24 h), followed by media change every other day. In vitro
corticogenesis occurs in the following weeks. Cultured cells were
then harvested or fixed at specific time points for further analysis.
Immunocytochemistry
Human iPSCs and iPSC-derived neural cells were fixed with 4%
paraformaldehyde (PFA) for 15 min at room temperature (RT).
Prior to immunocytochemistry, cells were permeabilized with 0.1%
Triton/phosphate-buffered saline (PBS) for 15 min at RT and
blocked with either 10% goat serum/PBS or 10% horse serum/PBS.
Primary antibodies used were as follows: OCT4 (1:100; Santa Cruz,
sc-5279), NANOG (1:100; Abcam, AB80892), Tra-1-60 (1:100; Santa
Cruz, sc-21705), SSEA4 (1:100; BD Bioscience, 560796), a-fetopro-
tein (1:150; R&D Systems, MAB1368), a-smooth muscle actin
(1:150; R&D Systems, MAB1420), Sox1 (1:100; R&D Systems,
AF3369), Sox2 (1:100; R&D Systems, 245610), Nestin (1:500;
Abcam, ab22035), Ki67 (1:100; BD Pharmingen, 550609), OTX2
(1:250; Millipore, AB9566), Pax6 (1:300; Biolegend, 901301),
vimentin (1:100; Abcam, ab28028), vGLUT1 (1:2000; Synaptic
systems, 135303), and b-III tubulin (Tuj1) (1:150; R&D System,
MAB1195). All primary antibodies were diluted in blocking solution
and incubated overnight at 4°C, followed by washing in PBS 3 times
for 15 min. Subsequently, appropriate Alexa Fluor 488 or 564 conju-
gated secondary antibodies were incubated for 1 h at RT. For nuclei
staining, samples were incubated with DAPI (Sigma-Aldrich) for
5 min and washed in PBS briefly. Finally, images were captured and
analyzed using IN Cell 2200 (GE Healthcare).
Immunoblot analysis
Wild-type mouse muscle and brain lysates (kind gift from Susan
Brown, Royal Veterinary College) were extracted as described [65].
Human iPSC-derived neural cells were harvested at specific time
points, and proteins were extracted in RIPA buffer consisting of
50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% Triton
X-100, 1% SDS, and 1 mM azide plus a cocktail of protease inhibi-
tors (Roche). A total of 30–60 lg of soluble protein was resolved
using NuPage Novex 4-12% Bis–Tris protein gels (Invitrogen) and
then electrophoretically transferred to polyvinylidene difluoride
(PVDF) membrane (Millipore). The PVDF membrane was blocked
in 3% bovine serum albumin in TBST (Tris-buffered saline with
0.1% Tween) and probed with primary antibodies to glycosylated a-
dystroglycan (IIH6 1:500; kind gift from Kevin Campbell, University
of Iowa), b-dystroglycan (1:100; Leica Biosystems, NCL-b-DG), and
dystroglycan core protein (1:200; R&D Systems, AF6868), followed
by washing with TBST and incubation with horseradish peroxidase
(HRP)-conjugated anti-mouse IgM (Millipore), HRP-conjugated anti-
mouse IgG (Jackson laboratories), and HRP-conjugated anti-sheep
IgG (1:1000; R&D Systems, HAF016), respectively. Note that anti-
beta actin antibody (1:1000; Abcam, ab8226) used in this study does
not cross-react with skeletal muscle actin. SuperSignal West Pico
Chemiluminescent Substrate (Thermo Fisher) was applied to PVDF
membranes and signals were visualized using a Bio-Rad ChemiDoc
MP imaging system and analyzed using ImageJ.
Laminin overlay analysis
Protein samples were extracted, resolved, and transferred to PVDF
membranes as described above. The PVDF membrane was then
blocked with 5% skimmed milk in laminin-binding buffer (LBB),
containing 10 mM triethanolamine, 140 mM NaCl, 1 mM MgCl2,
1 mM CaCl2 (pH adjusted to 7.6), followed by incubation with lami-
nins from Engelbreth–Holm–Swarm murine sarcoma basement
membrane (Sigma, L2020) in LBB with a final concentration of
5 lg/ml at 4°C overnight. The PVDF membrane was then incubated
with the pan-laminin antibody (1:1000; Sigma, L9393), washed with
1× LBB with 0.1% Tween, and incubated with HRP-conjugated anti-
rabbit IgG (Jackson laboratories). Signal detection using chemilumi-
nescence substrate was performed as above.
High-throughput compound screening
Cell line, compound library, and platform
H2K 2B4 myoblasts were grown at 33°C in 10% CO2 in medium
containing c-interferon (Chemicon) at a concentration of 20 U/ml.
The flasks were coated with 0.1 mg/ml Matrigel (BD bioscience)
diluted in DMEM (Gibco, Life Technology). The growth medium
consists of 20% fetal bovine serum (FBS, Gibco), 2% L-glutamine
(Sigma), and 1% penicillin/streptomycin (Gibco), plus 2% chick
embryo extract (Sera lab) and c-IFN (2 ll/ml, Merck). Large-scale
screening was performed on 31,954 chemical compounds from the
ChemiBank(UCL) collection (http://www.ucl.ac.uk/chemibank/)
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[66]. Molecular properties ranges were as follows: molecular weight
between 126 and 600, AlogP between 3.5 and 6, hydrogen bond
donors between 0 and 6, hydrogen bond acceptors between 0 and
12, rotatable bonds between 0 and 15, and number of rings between
1 and 8. The library has hit-like properties but is outside of Lipin-
ski’s rule of five. Compounds were stored as a 10 mM DMSO stock
solution under nitrogen (5% O2) and low humidity (5%) at room
temperature and in the dark (Roylan San Francisco storage pod). On
the day of the screening, 384-well plates (BD bioscience) were
coated with Matrigel and compounds were dispensed at the final
concentration of 10 lM by an acoustic dispenser (Labcyte Echo
520). Cells were detached from their flasks using trypsin–EDTA (Life
Technology), counted, diluted at the concentration of 10,000 cells/
50 ll, and then plated in the coated 384 well plates. The media for
the control wells (no compound added) contained 0.2% dimethyl
sulfoxide (DMSO, Sigma) to account for the DMSO present in the
compounds; as a positive control, cells were incubated with Tricho-
statin A (Sigma-Aldrich) 5 lM. After incubation for 24 h at 33°C,
the cells were fixed with 2% PFA for 40 min and then washed using
a Tecan HydroSpeed Plate Washer. The myoblasts were then incu-
bated with anti-a-dystroglycan IIH6 (Millipore) for 1 h, followed by
an anti-IgM-Alexa 488 (Life Technology) and Hoechst 33342 (Life
Technology) for 40 min. Stained cells were imaged on a Perki-
nElmer Opera LX (a confocal high-content screening microscope)
using the following light sources: UV Lamp (for Hoechst detection),
488 laser (for a-dystroglycan detection). Images were analyzed in
Columbus 2.4.1 (Perkin Elmer) and the abundance of glycosylated
a-dystroglycan was assessed. Briefly, cells were segmented and the
mean whole-cell intensity was determined using the 488 Channel.
The resulting intensity values were normalized to negative controls
in each plate, and z-scores were calculated using the CellHTS2
program for R [67].
Flow cytometry
H2K 2B4 cells were grown as described above in 75-cm2 flasks.
When the cells were approximately 80-90% confluent, they were
treated with compounds at various concentrations for 24 h at 33°C/
5% CO2. After 24 h, cells were detached using non-enzymatic cell
dissociation solution and fixed on ice with 2% paraformaldehyde
for 10 min. Cells were washed with PBS (Mg2+ and Ca2+ free) and
centrifuged and the pellets re-suspended with anti-a-dystroglycan
IIH6 antibody (1:200 in 0.1% FBS/PBS). For a negative control,
some cells were incubated without primary antibody and some with
0.2% dimethyl sulfoxide (DMSO, Sigma). Incubation was on ice for
30 min, followed by biotinylated anti-mouse IgM (1:100 in 0.1%
FBS/PBS) for 20 min, and streptavidin-PE (1:1,000 in 0.1% FBS/
PBS) for 15 min. Cells were then run on a Cyan ADP fitted with a
488 nm laser and a 633 nm red diode. The analysis was performed
using FlowJo software.
Expanded View for this article is available online.
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